The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment: Third in Molecular Medicine Review Series
Open accessAbstract
Duchenne muscular dystrophy (DMD) is caused by mutations in the gene that encodes the 427‐kDa cytoskeletal protein dystrophin. Increased knowledge of the function of dystrophin and its role in muscle has led to a greater understanding of the pathogenesis of DMD. This, together with advances in the genetic toolkit of the molecular biologist, are leading to many different approaches to treatment. Gene therapy can be achieved using plasmids or viruses, mutations can be corrected using chimaeraplasts and short DNA fragments, exon skipping of mutations can be induced using oligonucleotides and readthrough of nonsense mutations can be achieved using aminoglycoside antibiotics. Blocking the proteasome degradation pathway can stabilize any truncated dystrophin protein, and upregulation of other proteins can also prevent the dystrophic process. Muscle can be repopulated with myoblasts or stem cells. All, or a combination, of these approaches hold great promise for the treatment of this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle
Blake, D. J., Weir, A., Newey, S. E., & Davies, K. E. (2002) · Physiological Reviews · doi:10.1152/physrev.00028.2001 · Cited by 1,242
Self-citationConversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts
Partridge, T. A., Morgan, J. E., Coulton, G. R., Hoffman, E. P., & Kunkel, L. M. (1989) · Nature · doi:10.1038/337176a0 · Cited by 878
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 1×
“The use of antibodies to specifically block the action of either myostatin (a member of the transforming growth factor-β (TGF-β) superfamily; Bogdanovich et al, 2002), or tumour necrosis factor-α (TNF-α; Grounds & Torrisi, 2004), has led to the functional improvement of dystrophic muscle in the…”
BackgroundSampaolesi, M., Torrente, Y., Innocenzi, A., Tonlorenzi, R., D'Antona, G., Pellegrino, M. A., Barresi, R., Bresolin, N., De Angelis, M. G. C., Campbell, K. P., et al. (2003) · Science · doi:10.1126/science.1082254 · Cited by 641
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 1×
“Recent exciting results show that the adeno-associated virus type 6 (AAV-6) serotype provides very efficient delivery to many muscles by administration through the tail vein (Gregorevic et al, 2004).”
ResultAminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E., & Sweeney, H. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7866 · Cited by 585
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice
Wehling, M., Spencer, M. J., & Tidball, J. G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105110 · Cited by 530
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice
Barton, E. R., Morris, L., Musaro, A., Rosenthal, N., & Sweeney, H. L. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108071 · Cited by 451
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S.-A., Fletcher, S., Partridge, T. A., & Wilton, S. D. (2003) · Nature Medicine · doi:10.1038/nm897 · Cited by 398
Muscular dystrophies and the dystrophin–glycoprotein complex
Straub, V., & Campbell, K. P. (1997) · Current Opinion in Neurology · doi:10.1097/00019052-199704000-00016 · Cited by 383
Cited by
Cooper, T. A., Wan, L., & Dreyfuss, G. (2009) · Cell · doi:10.1016/j.cell.2009.02.011 · Cited by 1,159
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Paediatric genomics: diagnosing rare disease in children
Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.116 · Cited by 618
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy
Gao, X., Ran, N., Dong, X., Zuo, B., Yang, R., Zhou, Q., Moulton, H. M., Seow, Y., & Yin, H. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0195 · Cited by 426
“Pathological improvement was dem onstrated by relocalization of dystrophinassociated protein complex (DAPC) components (28), which fail to localize to the sarcolemma in the absence of dys trophin, 0 500 1000 1500”
MethodMolecular mechanisms of muscular dystrophies: old and new players
Davies, K. E., & Nowak, K. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2024 · Cited by 349
Self-citationGrounds, M. D., Radley, H. G., Lynch, G. S., Nagaraju, K., & De Luca, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.03.008 · Cited by 344
Mamchaoui, K., Trollet, C., Bigot, A., Negroni, E., Chaouch, S., Wolff, A., Kandalla, P. K., Marie, S., Di Santo, J., St Guily, J. L., et al. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-34 · Cited by 340
Mourkioti, F., Kratsios, P., Luedde, T., Song, Y.-H., Delafontaine, P., Adami, R., Parente, V., Bottinelli, R., Pasparakis, M., & Rosenthal, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28721 · Cited by 315
NF-kB and Inflammatory Cytokine Signalling: Role in Skeletal Muscle Atrophy
Thoma, A., & Lightfoot, A. P. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-1435-3_12 · Cited by 313
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
The AlphaFold Database of Protein Structures: A Biologist’s Guide
David, A., Islam, S., Tankhilevich, E., & Sternberg, M. J. E. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167336 · Cited by 268
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y.-K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 264
Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane
Yoshida-Moriguchi, T., & Campbell, K. P. (2015) · Glycobiology · doi:10.1093/glycob/cwv021 · Cited by 252
Doncevic, D., & Herrmann, C. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad387 · Cited by 51
Zhao, C., Farruggio, A. P., Bjornson, C. R. R., Chavez, C. L., Geisinger, J. M., Neal, T. L., Karow, M., & Calos, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096279 · Cited by 25
Metadata
- Authors
- Nowak, K. J., & Davies, K. E.
- Venue
- EMBO reports
- Published
- 2004-09
- Volume
- 5
- Issue
- 9
- Pages
- 872-876
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2049094551
- Cited by
- 357
- References
- 47
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.